Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works. Before starting Apidra(R), tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed.
Indications and Usage
Prescription Apidra(R) is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra(R) is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra(R) should be given within 15 minutes before or within 20 minutes after starting a meal.
Apidra(R) SoloSTAR(R) is a disposable prefilled insulin pen.
For full prescribing information for Apidra(R), please visit http://www.Apidra.com or call +44(0)800-633-1610.
About Diabetes
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. It is estimated that approximately 285 million adults worldwide are living with the disease and this number is expected to rise to a staggering 438 million within 20 years[iii],[iv]. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed[v] At the same time, according to NHANES data from 2003-2004, approximately 40 percent of those diagnosed with diabetes did not achieve the blood sugar control target of A1C <7 percent recommended by the ADA[vi]. The A1C test measures average blood glucose levels over the past two-to-three-month period.
About the sanofi-aventis Diabetes Division
Sanofi-aventis strives to be a 360 degree partner delivering innovative and integrated solutions for people living with diabetes. The Company currently has insulin products, including Lantus(R), Apidra(R) and Insuman(R) (outside the US)-- Lantus(R) and Apidra(R) are also available as injection pens (Lantus(R) SoloSTAR(R) and Apidra(R) SoloSTAR(R)). Also available in some countries (outside the US) is ClikSTAR(R), a reusable insulin injection pen for Lantus(R) or Apidra(R) for people with type 1 or type 2 diabetes. Following the formation of its Diabetes Division, sanofi-aventis has agreements with other companies for the development of blood glucose monitoring solutions and the potential first regenerative treatment for diabetes. Investigational compounds also in the pipeline include the once-daily injectable GLP-1 agonist lixisenatide as a monotherapy and in combination with basal insulin as well as long-acting insulin analogs.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: http://www.sanofi-aventis.com.
US.GLA.10.08.098
[i] Banerji, M.A., "Efficacy and Goal Attainment with Insulin Glargine vs
Comparators." Presented at the European Association for the Study of
Diabetes 46th Annual Meeting, presentation number 976,2010.
[ii] Leahy, J. "Clinical outcomes after basal insulin initiation
correlate with baseline oral antidiabetic drug therapy: a pooled
analysis of clinical trial data." Presented at the Association for
the Study of Diabetes 46th Annual Meeting, presentation number 960,
2010.
[iii] IDF Diabetes Atlas.Global Burden.Aug.2010/Page 1/Lines 26-27
[iv] IDF Diabetes Atlas.Global Burden.Aug.2010/Page 1/Lines 29-30
[v] CDC.DiabetesFactSheet.2007/Pg 5/Line 20]
[vi]Ford.DiabetesCare.Jan.2008/Pg 103/Table 1
Media Contacts: Susan Brooks, US: Tel: +1-908-981-6566, E-mail: Susan.Brooks@sanofi-aventis.com; Yanyan Chang, Global Diabetes Division: Tel: +49-69-305-22283, E-mail: Yanyan.chang@sanofi-aventis.com; Marisol Peron, Corporate Media Relations, Tel: +33(0)1-53-77-45-02, Mobile : +33(0)6-08-18-94-78, E-mail: marisol.peron@sanofi-aventis.com
